Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults

Exclusion Criteria

• •For enrolment to the primary \& booster phase:
• •Any confirmed or suspected immunosuppressive or immunodeficient condition, including immunodeficiency virus (HIV) infection.
• •Acute disease and/or fever at the time of enrolment to booster phase.
• •* Acute disease is defined as the presence of a moderate or severe illness with or without fever. Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
• •* Fever is defined as temperature ≥ 38.0°C (100.4°F) on oral, axillary or tympanic setting. The preferred route for recording temperature in this study will be oral.
• •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
• •Evidence of increased cardiovascular disease risk, "moderate" or "high", according to the National health and nutrition examination survey I (NHANES I) criteria.
• •Note: NHANES I criteria will be applied for all subjects including subjects aged 18-35 years old.
• •An abnormal baseline screening electrocardiogram (EKG), defined as one showing pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial contractions; right or left bundle branch block; or advanced A-V heart block.
• •Female who intends to become pregnant during the study or planning to discontinue contraceptive measures.
• •For enrolment to the primary phase:
• •Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
• •Planned administration/administration of a vaccine not foreseen by the study protocol within 7 days of the first dose of vaccines.
• •Prior receipt of an investigational malaria vaccine.
• •Chronic use of antibiotics with antimalarial effects.
• •History of malaria chemoprophylaxis within 60 days prior to vaccination.
• •Any history of malaria.
• •Planned travel to malaria endemic areas during the study period.
• •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s) including latex.
• •History of allergic disease or reactions likely to be exacerbated by chloroquine.
• •History of psoriasis and porphyria, which may be exacerbated after chloroquine treatment.
• •Current use of medications known to cause drug reactions to chloroquine.
• •Any history of anaphylaxis in reaction to any previous vaccination.
• •History of severe reactions to mosquito bites.
• •Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
• •Chronic administration of immunosuppressants or other immune modifying drugs within six months prior to first vaccine dose. For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 20 mg/day. Inhaled and topical steroids are allowed.
• •Family history of congenital or hereditary immunodeficiency.
• •History of splenectomy.
• •Major congenital defects or serious chronic illness.
• •History of any neurological disorders or seizures, except for a single episode of simple febrile seizure in childhood.
• •Any abnormal baseline laboratory screening tests: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), creatinine, hemoglobin, platelet count, total white blood cell count, out of normal range as defined in the protocol.
• •Hepatomegaly, right upper quadrant abdominal pain or tenderness.
• •Personal history of autoimmune disease.
• •Seropositive for hepatitis B surface antigen or Hepatitis C virus.
• •Pregnant or lactating female.
• •Suspected or known current alcohol abuse.
• •Chronic or active intravenous drug use.
• •History of blood donation within 56 days preceding enrolment.
• •Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.
• •For enrolment to the booster phase:
• •Planned use of any investigational or non-registered product other than the study vaccine during the study period.
• •Planned administration/administration of a vaccine not foreseen by the study protocol within 7 days of booster dose of study vaccine.
• •Planned administration of immunoglobulins and/or any blood products during the study period.
• •An abnormal baseline laboratory screening test, graded 2 or more as defined in the protocol.
• •Any abnormal baseline laboratory screening tests out of normal range as defined in the protocol and of clinical concern according to the Principal Investigator.
• •Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in the booster phase of the study.